Co-Diagnostics, Inc.

For the period ended Mar 31, 2026. Filed May 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 14, 2026

CODX$0.32+24.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Three Months Ended March 31,
2026 · 2025
Product revenue		$145,954	$50,277
Total revenue		145,954	50,277
Cost of revenue		193,768	21,590
Gross profit (loss)		(47,814)	28,687
Operating expenses
Sales and marketing		467,955	657,030
General and administrative		2,503,126	2,773,149
Research and development		5,934,071	4,870,019
Depreciation and amortization		255,445	280,445
Total operating expenses		9,160,597	8,580,643
Loss from operations		(9,208,411)	(8,551,956)
Other income, net
Interest income, net		6,974	13,601
Realized gain on investments		-	301,465
Gain on remeasurement of acquisition contingencies		75,280	717,067
Loss on equity method investment in joint ventures		(13,361)	(1,444)
Total other income, net		68,893	1,030,689
Loss before income taxes		(9,139,518)	(7,521,267)
Income tax provision		520	12,004
Net loss		$(9,140,038)	$(7,533,271)
Other comprehensive income (loss)
Change in net unrealized gains (losses) on marketable securities, net of tax		-	(87,790)
Total other comprehensive income (loss)	$	-	$(87,790)
Comprehensive loss		$(9,140,038)	$(7,621,061)
Loss per common share:
Basic and Diluted		$(4.06)	$(7.05)
Weighted average shares outstanding:
Basic and Diluted		2,253,474	1,068,299

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.